Should I buy or sell Immunocore stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IMCR shares. View IMCR analyst ratings or view top-rated stocks .

What is Immunocore's stock price target for 2024?

12 brokerages have issued 12 month price objectives for Immunocore's stock. Their IMCR share price targets range from $63.00 to $91.00. On average, they predict the company's stock price to reach $80.55 in the next twelve months. This suggests a possible upside of 44.5% from the stock's current price. View analysts price targets for IMCR or view top-rated stocks among Wall Street analysts .

How have IMCR shares performed in 2024?

Immunocore's stock was trading at $68.32 on January 1st, 2024. Since then, IMCR shares have decreased by 18.4% and is now trading at $55.73. View the best growth stocks for 2024 here .

Are investors shorting Immunocore?

Immunocore saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,610,000 shares, an increase of 7.5% from the March 15th total of 4,290,000 shares. Based on an average daily volume of 491,700 shares, the short-interest ratio is presently 9.4 days. Approximately 9.5% of the company's shares are sold short. View Immunocore's Short Interest .

When is Immunocore's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our IMCR earnings forecast .

How were Immunocore's earnings last quarter?

Immunocore Holdings plc (NASDAQ:IMCR) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.12. The business earned $70.16 million during the quarter, compared to analysts' expectations of $53.25 million. Immunocore had a negative net margin of 22.48% and a negative trailing twelve-month return on equity of 15.78%. The firm's revenue for the quarter was up 22.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.63) EPS.

What ETFs hold Immunocore's stock?

ETFs with the largest weight of Immunocore (NASDAQ:IMCR) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM) , ALPS Medical Breakthroughs ETF (SBIO) , Virtus LifeSci Biotech Products ETF (BBP) , Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA) . BlackRock Future Health ETF (BMED) .

When did Immunocore IPO?

Immunocore (IMCR) raised $199 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,300,000 shares at $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO.

Who are Immunocore's major shareholders?

Immunocore's stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.18%) and Hennion & Walsh Asset Management Inc. (0.04%). View institutional ownership trends .

How do I buy shares of Immunocore?

Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IMCR

Immunocore (IMCR) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free IMCR Stock Alerts

$55.68

+0.94 (+1.72%)

(As of 04:00 PM ET)

Compare

Today's Range: $53.79
▼
$56.15
50-Day Range: $53.37
▼
$74.61
52-Week Range: $42.21
▼
$76.98

Volume: 447,723 shs
Average Volume: 488,466 shs
Market Capitalization: $2.77 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $80.55

Get Immunocore alerts:

Immunocore MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 44.5% Upside
$80.55 Price Target
Short Interest: Bearish
9.49% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.76
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.54) to ($1.95) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.18 out of 5 stars

Medical Sector

588th out of 918 stocks

Biological Products, Except Diagnostic Industry

95th out of 151 stocks

4.4

Analyst's Opinion

Consensus Rating
Immunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Immunocore has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
9.49% of the float of Immunocore has been sold short.
Short Interest Ratio / Days to Cover
Immunocore has a short interest ratio ("days to cover") of 9.4.
Change versus previous month
Short interest in Immunocore has recently increased by 7.46%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Immunocore does not currently pay a dividend.
Dividend Growth
Immunocore does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMCR.

2.6

News and Social Media Coverage

News Sentiment
Immunocore has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Immunocore this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for IMCR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immunocore insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.70% of the stock of Immunocore is held by insiders.
Percentage Held by Institutions
84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Immunocore are expected to decrease in the coming year, from ($1.54) to ($1.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immunocore is -48.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immunocore is -48.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immunocore has a P/B Ratio of 7.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Immunocore Stock (NASDAQ:IMCR)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

IMCR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMCR Stock News Headlines

April 16, 2024 | americanbankingnews.com

Immunocore Holdings plc (NASDAQ:IMCR) Sees Significant Increase in Short Interest

April 13, 2024 | americanbankingnews.com

Immunocore (NASDAQ:IMCR) Rating Reiterated by Needham & Company LLC

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 11, 2024 | markets.businessinsider.com

Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)

April 10, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - IMCR

April 5, 2024 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)

April 5, 2024 | investing.com

Immunocore executive sells shares worth over $280,000

April 4, 2024 | globenewswire.com

Immunocore to present at upcoming investor conferences

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 16, 2024 | finance.yahoo.com

IMCR Apr 2024 45.000 put

March 16, 2024 | finance.yahoo.com

IMCR Apr 2024 95.000 call

March 11, 2024 | markets.businessinsider.com

Castle Biosciences: A Strong Buy on Genomic Diagnostic Leadership and Market Growth Potential

March 6, 2024 | markets.businessinsider.com

Buy Rating on Immunocore Holdings: Robust Financials and Promising Pipeline Signal Growth

March 5, 2024 | globenewswire.com

Immunocore presented two posters at CROI 2024

March 1, 2024 | seekingalpha.com

Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript

March 1, 2024 | globenewswire.com

Immunocore to present at upcoming investor conferences

February 29, 2024 | markets.businessinsider.com

Key Takeaways From Immunocore Hldgs Analyst Ratings

February 29, 2024 | finance.yahoo.com

Immunocore Holdings plc (NASDAQ:IMCR) Q4 2023 Earnings Call Transcript

February 28, 2024 | finance.yahoo.com

Immunocore Holdings PLC (IMCR) Reports Strong Revenue Growth Amidst Expansion and Clinical ...

February 28, 2024 | msn.com

Immunocore GAAP EPS of -$0.40 misses by $0.13, revenue of $70.16M beats by $1.79M

February 28, 2024 | globenewswire.com

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

February 27, 2024 | msn.com

Immunocore FY 2023 Earnings Preview

February 24, 2024 | investing.com

Immunocore Holdings Ltd (IMCR)

February 22, 2024 | globenewswire.com

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

February 21, 2024 | finance.yahoo.com

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

February 21, 2024 | globenewswire.com

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

February 14, 2024 | finance.yahoo.com

Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology

See More Headlines

Receive IMCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:IMCR
CUSIP: N/A
CIK: 1671927
Web: www.immunocore.com
Phone: 44-12-3543-8600
Fax: N/A
Employees: 497
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $80.55
High Stock Price Target: $91.00
Low Stock Price Target: $63.00
Potential Upside/Downside: +47.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-55,290,000.00
Net Margins: -22.48%
Pretax Margin: -24.41%
Return on Equity: -15.78%
Return on Assets: -9.91%

Debt

Debt-to-Equity Ratio: 0.13
Current Ratio: 3.80
Quick Ratio: 3.77

Sales & Book Value

Annual Sales: $249.43 million
Price / Sales: 10.93
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.42 per share
Price / Book: 7.38

Miscellaneous

Outstanding Shares: 49,820,000
Free Float: 46,981,000
Market Cap: $2.73 billion
Optionable: Optionable
Beta: 0.89

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Bahija Jallal Ph.D. (Age 63)
CEO & Director
Comp: $1.42M
Mr. Brian R. Di Donato M.B.A. (Age 57)
CFO & Head of Strategy
Mr. John Trainer M.B.A. (Age 50)
SVP & Chief Operating Officer
Mr. John Goll III
SVP, Finance & Chief Accounting Officer
Ms. Annelise Vuidepot Ph.D.
CTO and Head of Pipeline & Platform Research
Mr. Sean D. Buckley (Age 41)
VP & Chief Information Officer
Clayton Robertson
Head of Investor Relations
Ms. Lily Margaret Hepworth
General Counsel & Company Secretary
Ms. Elizabeth Varki Jobes Esq. (Age 57)
J.D., Chief Compliance Officer
Mr. Sébastien Desprez
Head of Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IMCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunocore stock right now?: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IMCR shares.
View IMCR analyst ratings or view top-rated stocks.
What is Immunocore's stock price target for 2024?: 12 brokerages have issued 12 month price objectives for Immunocore's stock. Their IMCR share price targets range from $63.00 to $91.00. On average, they predict the company's stock price to reach $80.55 in the next twelve months. This suggests a possible upside of 44.5% from the stock's current price.
View analysts price targets for IMCR or view top-rated stocks among Wall Street analysts.
How have IMCR shares performed in 2024?: Immunocore's stock was trading at $68.32 on January 1st, 2024. Since then, IMCR shares have decreased by 18.4% and is now trading at $55.73.
View the best growth stocks for 2024 here.
Are investors shorting Immunocore?: Immunocore saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,610,000 shares, an increase of 7.5% from the March 15th total of 4,290,000 shares. Based on an average daily volume of 491,700 shares, the short-interest ratio is presently 9.4 days. Approximately 9.5% of the company's shares are sold short.
View Immunocore's Short Interest.
When is Immunocore's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our IMCR earnings forecast.
How were Immunocore's earnings last quarter?: Immunocore Holdings plc (NASDAQ:IMCR) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.12. The business earned $70.16 million during the quarter, compared to analysts' expectations of $53.25 million. Immunocore had a negative net margin of 22.48% and a negative trailing twelve-month return on equity of 15.78%. The firm's revenue for the quarter was up 22.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.63) EPS.

What ETFs hold Immunocore's stock?: ETFs with the largest weight of Immunocore (NASDAQ:IMCR) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).BlackRock Future Health ETF (BMED).
When did Immunocore IPO?: Immunocore (IMCR) raised $199 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,300,000 shares at $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO.
Who are Immunocore's major shareholders?: Immunocore's stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.18%) and Hennion & Walsh Asset Management Inc. (0.04%).
View institutional ownership trends.
How do I buy shares of Immunocore?: Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMCR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immunocore (IMCR) Stock Price, News & Analysis

Immunocore MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Immunocore Stock (NASDAQ:IMCR)

IMCR Stock Price History

IMCR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IMCR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™